Chemotherapy in the treatment of metastatic gastric cancer: Is There a global standard?

Hyunseok Kang, John S. Kauh

Research output: Contribution to journalArticle

Abstract

Gastric cancer remains one of the leading causes of cancer mortality worldwide even though its incidence has been decreasing in recent years. Despite remarkable advancements in chemotherapy, advanced gastric cancer has remained a therapeutic challenge for physicians as well as for patients. While early chemotherapeutic regimens succeeded in showing a modest but definite improvement over best supportive care, no single regimen stood out as superior. Most early trials failed to show survival benefit of combination regimens over single agent fluorouracil, but combination regimens were shown to have better response rates. Based on these data, the Japanese adopted single agent fluorouracil as a reference standard for further investigations, while the rest of the world used a doublet containing fluorouracil and platinum. As more clinical trials were conducted, the Japanese standard evolved into a doublet, while the Western countries adopted triplet combinations. There is no established global standard as yet, but with the introduction of newer targeted agents based on molecular assays and personalized approaches combined with conventional chemotherapy, multiple regimens are likely to emerge as global standards rather than one standard treatment for all.

Original languageEnglish (US)
Pages (from-to)96-106
Number of pages11
JournalCurrent Treatment Options in Oncology
Volume12
Issue number1
DOIs
StatePublished - Mar 2011
Externally publishedYes

Fingerprint

Stomach Neoplasms
Drug Therapy
Fluorouracil
Therapeutics
Platinum
Clinical Trials
Physicians
Survival
Mortality
Incidence
Neoplasms

ASJC Scopus subject areas

  • Oncology
  • Pharmacology (medical)

Cite this

Chemotherapy in the treatment of metastatic gastric cancer : Is There a global standard? / Kang, Hyunseok; Kauh, John S.

In: Current Treatment Options in Oncology, Vol. 12, No. 1, 03.2011, p. 96-106.

Research output: Contribution to journalArticle

@article{a4f6b2b426b9430889444fbaf83bce52,
title = "Chemotherapy in the treatment of metastatic gastric cancer: Is There a global standard?",
abstract = "Gastric cancer remains one of the leading causes of cancer mortality worldwide even though its incidence has been decreasing in recent years. Despite remarkable advancements in chemotherapy, advanced gastric cancer has remained a therapeutic challenge for physicians as well as for patients. While early chemotherapeutic regimens succeeded in showing a modest but definite improvement over best supportive care, no single regimen stood out as superior. Most early trials failed to show survival benefit of combination regimens over single agent fluorouracil, but combination regimens were shown to have better response rates. Based on these data, the Japanese adopted single agent fluorouracil as a reference standard for further investigations, while the rest of the world used a doublet containing fluorouracil and platinum. As more clinical trials were conducted, the Japanese standard evolved into a doublet, while the Western countries adopted triplet combinations. There is no established global standard as yet, but with the introduction of newer targeted agents based on molecular assays and personalized approaches combined with conventional chemotherapy, multiple regimens are likely to emerge as global standards rather than one standard treatment for all.",
author = "Hyunseok Kang and Kauh, {John S.}",
year = "2011",
month = "3",
doi = "10.1007/s11864-010-0135-z",
language = "English (US)",
volume = "12",
pages = "96--106",
journal = "Current Treatment Options in Oncology",
issn = "1527-2729",
publisher = "Springer New York",
number = "1",

}

TY - JOUR

T1 - Chemotherapy in the treatment of metastatic gastric cancer

T2 - Is There a global standard?

AU - Kang, Hyunseok

AU - Kauh, John S.

PY - 2011/3

Y1 - 2011/3

N2 - Gastric cancer remains one of the leading causes of cancer mortality worldwide even though its incidence has been decreasing in recent years. Despite remarkable advancements in chemotherapy, advanced gastric cancer has remained a therapeutic challenge for physicians as well as for patients. While early chemotherapeutic regimens succeeded in showing a modest but definite improvement over best supportive care, no single regimen stood out as superior. Most early trials failed to show survival benefit of combination regimens over single agent fluorouracil, but combination regimens were shown to have better response rates. Based on these data, the Japanese adopted single agent fluorouracil as a reference standard for further investigations, while the rest of the world used a doublet containing fluorouracil and platinum. As more clinical trials were conducted, the Japanese standard evolved into a doublet, while the Western countries adopted triplet combinations. There is no established global standard as yet, but with the introduction of newer targeted agents based on molecular assays and personalized approaches combined with conventional chemotherapy, multiple regimens are likely to emerge as global standards rather than one standard treatment for all.

AB - Gastric cancer remains one of the leading causes of cancer mortality worldwide even though its incidence has been decreasing in recent years. Despite remarkable advancements in chemotherapy, advanced gastric cancer has remained a therapeutic challenge for physicians as well as for patients. While early chemotherapeutic regimens succeeded in showing a modest but definite improvement over best supportive care, no single regimen stood out as superior. Most early trials failed to show survival benefit of combination regimens over single agent fluorouracil, but combination regimens were shown to have better response rates. Based on these data, the Japanese adopted single agent fluorouracil as a reference standard for further investigations, while the rest of the world used a doublet containing fluorouracil and platinum. As more clinical trials were conducted, the Japanese standard evolved into a doublet, while the Western countries adopted triplet combinations. There is no established global standard as yet, but with the introduction of newer targeted agents based on molecular assays and personalized approaches combined with conventional chemotherapy, multiple regimens are likely to emerge as global standards rather than one standard treatment for all.

UR - http://www.scopus.com/inward/record.url?scp=79957997894&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79957997894&partnerID=8YFLogxK

U2 - 10.1007/s11864-010-0135-z

DO - 10.1007/s11864-010-0135-z

M3 - Article

C2 - 21274667

AN - SCOPUS:79957997894

VL - 12

SP - 96

EP - 106

JO - Current Treatment Options in Oncology

JF - Current Treatment Options in Oncology

SN - 1527-2729

IS - 1

ER -